|
T38078 |
TLR7/8-IN-1
|
TLR7/8-IN-1 |
TLR
|
|
TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor, is a valuable compound for autoimmune disease research[1]. |
|
T5561 |
TLR7/8 agonist 1 dihydrochloride
|
TLR7/8 agonist-5d |
TLR
|
|
TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) is a TLR7/8 agonist which shows prominent immunostimulatory activities. |
|
T39669 |
TLR7/8/9-IN-1
|
TLR7/8/9-IN-1 |
TLR
|
|
TLR7/8/9-IN-1 is a potent inhibitor of Toll-like receptors 7/8/9 (TLR7/8/9) with an IC50 of 43 nM. |
|
T13167 |
TLR7/8 agonist 3
|
|
TLR
|
|
TLR7/8 agonist 3 is a potent agonist of TLR7 and TLR8. |
|
T39969 |
TLR7/8 agonist 4 TFA
|
|
|
|
TLR7/8 agonist 4 TFA (compound 41) is a highly potent TLR7/8 agonist that exhibits significant anti-cancer activity. |
|
T72035 |
TLR7/8/9 antagonist 2
|
|
TLR
|
|
TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/... |
|
T39968 |
TLR7/8 agonist 4 hydroxy-PEG10-acid
|
TLR7/8 agonist 4 hydroxy-PEG10-acid |
|
|
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugate employed in antibody-drug conjugates (ADC). This compound exhibits remarkable antitumor activity by utilizing TLR7/8 agonist 4, which acts as a ... |
|
T39970 |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
|
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride |
|
|
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate used in antibody-drug conjugates (ADCs) with high efficacy against tumors. It consists of TLR7/8 agonist 4, a potent TLR7/8 agonis... |
|
T71108 |
TLR7/8 agonist 1
|
|
|
|
TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline. |
|
T9570 |
Enpatoran
|
|
TLR
|
|
Enpatoran is an inhibitor of TLR7(IC50 = 11.1 nM) and TLR8(IC50 = 24.1 nM). Enpatoran was found to be inactive against TLR3, TLR4, and TLR9 in vitro and in vivo. |
|
T79068 |
TLR7/8 agonist 8
|
|
|
|
TLR7/8 agonist 8 (compound 24m) is a potent dual agonist for toll-like receptors 7 and 8 (TLR7/8), exhibiting half-maximal effective concentrations (EC50s) of 27 nM for human TLR7 (hTLR7) and 12 nM for human TLR8 (hTLR8)... |
|
T62178 |
TLR7/8 antagonist 1
|
|
|
|
TLR7/8 Antagonist 1 (Compound 16c), an imidazoquinoline derivative, is a potent TLR7/8 agonist with IC50 values of 3.91 and 2.19 μM for TLR7 and TLR8, respectively. rel-O-2050 (TLR-2050) is a key target for drug developm... |
|
T64606 |
TLR7/8 agonist-7d
|
|
|
|
TLR7/8 agonist-7d is a useful organic compound for research related to life sciences and the catalog number is T64606. |
|
T60894 |
TLR7/8 agonist 4
|
|
|
|
TLR7/8 agonist 4 (compound 41) is a potent agonist of TLR7/8 with anti-cancer activity [1]. |
|
T62177 |
TLR7/8 agonist 6
|
|
|
|
TLR7/8 agonist 6 (Compound 4), an imidazoquinoline derivative, is a potent TLR7/8 agonist with IC50 values of 0.18 and 5.34 μM for TLR7 and TLR8, respectively. TLR7/8 Antagonist |
|
T61601 |
TLR7/8 antagonist 2
|
|
|
|
TLR7/8 antagonist 2 (Compound 15) is a highly potent and orally active agonist of TLR7/8, exhibiting IC50 values of 4.9 and 0.6 nM for TLR7 and TLR8, respectively. Its strong affinity for these receptors makes it a promi... |
|
T72684 |
TLR7/8 agonist 7
|
|
|
|
TLR7/8 agonist 7, a compound that functions as a TLR7/8 agonist, plays a pivotal role in activating various immune cells and is instrumental in the synthesis of immune-stimulating antibody conjugate (ISAC) molecules. Thi... |
|
T79069 |
TLR7/8 agonist 9
|
|
|
|
TLR7/8 agonist 9 (Compound 25a), exhibiting EC50 values of 40 nM and 23 nM for hTLR7 and hTLR8 respectively, demonstrates anti-tumor properties and enhances the efficacy of PD-1/PD-L1 blockade treatments. This compound i... |
|
T80976 |
TLR7/8 agonist 4 hydroxy-PEG6-acid
|
|
|
|
TLR7/8 agonist 4 hydroxy-PEG6-acid, a Drug-Linker Conjugate for ADCs, comprises the TLR7/8 agonist 4 and a hydroxy-PEG6-acid linker, suitable for the synthesis of antibody-drug conjugates (ADCs) [1]. |
|
T77890 |
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
|
|
|
|
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride, a Drug-Linker Conjugate for ADC synthesis, is the hydrochloride variant of TLR7/8 agonist 4 hydroxy-PEG6-acid, comprising the TLR7/8 agonist 4 component attached to the h... |
|
T15371 |
Gardiquimod
|
|
TLR
,
HIV Protease
|
|
Gardiquimod is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells... |
|
T6898 |
Motolimod
|
VTX-378,VTX-2337 |
TLR
|
|
Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7. |
|
T17032 |
Telratolimod
|
MEDI9197,3M-052 |
TLR
|
|
Telratolimod (MEDI9197) is a toll-like receptors 7/8 agonist. It has an antitumor activity. |
|
T6964 |
Resiquimod
|
R848,S28463 |
HCV Protease
,
TLR
|
|
Resiquimod (R848) is an imidazoquinoline amine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and acti... |
|
T13182 |
Toll-like receptor modulator
|
|
TLR
|
|
Toll-like receptor modulator is a TLR7/8 modulator, which modulates immune function. |
|
TNU1309 |
TLR7 agonist 10
|
|
|
|
TLR7 agonist 10 is a Nucleoside Derivative - Xylo-nucleoside, N-Methylated alkylated nucleoside; 8-Modified purine nucleoside. |
|
T74348 |
HE-S2
|
|
PD-1/PD-L1
|
|
HE-S2, an antibody-drug conjugate, elicits a potent antitumor immune response by inhibiting the PD-1/PD-L1 interaction and stimulating the Toll-like receptor 7/8 (TLR7/8) signaling pathway, resulting in significant antit... |
|
T14035 |
3M-011
|
|
TLR
|
|
3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibit... |
|
T5499 |
Gardiquimod TFA salt
|
|
|
|
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically ... |
|
T37287 |
Enpatoran hydrochloride
|
|
|
|
Enpatoran (M5049) hydrochloride is a potent and orally active dual inhibitor of TLR7/8 with IC50 values of 11.1 nM and 24.1 nM in HEK293 cells, respectively. This compound specifically inhibits TLR7 and TLR8, while showi... |
|
T61390 |
D18
|
|
|
|
D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increa... |
|
T83895 |
NCI 126224
|
NSC 126224 |
|
|
NCI 126224, a toll-like receptor 4 (TLR4) antagonist, demonstrates selective inhibition of nitric oxide (NO) production in RAW 264.7 macrophages, triggered by the TLR4 agonist LPS (IC50 = 0.31 µM), as opposed to minimal ... |
